Advanced Filters
noise
Found 1,216 clinical trials
N Nanxue Duan

Transcranial Direct Current Stimulation for Depression

Background Depression is a common mental disorder characterized by persistent low mood and anhedonia. Pharmacological and psychotherapeutic treatments demonstrate only moderate efficacy. Non-invasive brain stimulation techniques offer novel therapeutic approaches. Among these, transcranial direct current stimulation (tDCS) holds advantages due to its simplicity, low cost, and minimal side effects, exhibiting …

18 - 65 years of age All Phase N/A
C Caroline Wass

Prospective Cohort Study of Response and Tolerability of Accelerated Intermittent Theta-burst Stimulation (1W-AiTBS)

Intermittent theta-burst stimulation (iTBS), a variant of repetitive transcranial magnetic stimulation (rTMS), is a well-documented treatment for depression. The aim of this study is to evaluate the effectiveness of an accelerated iTBS protocol (1W-AiTBS) in routine clinical practice. In the accelerated protocol, patients receive 600 pulses per session, for a …

18 years of age All Phase N/A
J Jennifer Dahne, PhD

Digitally Enhanced Stepped-Care for Depression in Primary Care

This pilot, three-arm randomized clinical trial (N=40; 2:1:1) will evaluate the feasibility and preliminary efficacy of a digitally enhanced stepped-care approach for depression treatment in primary care. Participants will be randomized to: (1) stepped-care beginning with a self-guided Behavioral Activation app (Moodivate), with stepping to clinician-delivered telebehavioral health Behavioral Activation …

18 years of age All Phase N/A
D Danyal Smani, MD

Mindfulness Training During Accelerated TMS for Depression

This NIH-funded single-arm pilot tests the feasibility, acceptability, and preliminary effects of embedding brief guided mindfulness practice (via the Waking Up smartphone app) into the inter-session intervals of clinically administered accelerated intermittent theta-burst stimulation (aiTBS) for major depressive disorder (MDD). Participants receive aiTBS as standard clinical care at MUSC; the …

18 - 80 years of age All Phase N/A
O Olusola Ajilore, MD, PhD

Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression

The goal of this study is to find out if the antihistamine, clemastine, can make the white matter in the brain better in older adults with depression. The study will also determine whether this improvement can make antidepressant treatment work better, reduce depressive symptoms, and improve memory and thinking.

60 years of age All Phase 2
M María Teresa González Salvador

Cerebral and Anti-inflammatory Response Through Exercise - Mechanisms In Depressive Disorders

The goal of this clinical trial is to study how physical exercise works when applied to patients diagnosed with Major Depressive Disorder (MDD). The main questions it aims to answer are: What are the antiinflammatory and oxidative stress and neural mechanisms involved in the antidepressant effects of exercise? How effective …

18 - 65 years of age All Phase N/A
S Sara Tremblay, PhD

Comparing the Efficacy of fMRI-Guided vs. Standard iTBS in Treating Depression

In this triple-blind randomized controlled trial, we ask if targeting intermittent theta burst stimulation (iTBS) based on individual resting state connectivity improves treatment outcomes in major depressive disorder (MDD). For the trial, we will recruit 210 patients with major depressive disorder. Each patient will undergo a 30-40-minute MRI scan, after …

18 years of age All Phase N/A
L Luise Pruessner, M.Sc.

Effectiveness of an Ecological Momentary Emotion Regulation Intervention

This two-armed randomized controlled trial aims to investigate the effectiveness of an emotion regulation intervention in individuals with and without depressive disorders. The study encompasses participants diagnosed with mild to moderate major depression or persistent depressive disorder and healthy controls without a current depressive disorder. Participants will be randomly assigned …

18 - 65 years of age All Phase N/A
A Albert Garcia-Romeu, Ph.D.

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

This open-label pilot study examines whether the hallucinogenic drug, psilocybin, given under supportive conditions, is safe and effective for depression in people with Mild Cognitive Impairment (MCI) or early Alzheimer's Disease (AD). This study will also assess whether psilocybin may improve quality of life in those individuals.

18 - 85 years of age All Phase 0
J Jennifer Dahne, PhD

IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)

The purpose of this research study is to evaluate a mobile application (app) for depression treatment called "Moodivate" among cancer survivors. Moodivate was developed by our research team to assist with the treatment of depressed mood. Participants will be randomly assigned to either download the mobile app, "Moodivate", or not. …

18 years of age All Phase N/A

Simplify language using AI